NCT04693650
A Prospective, Multi-site, Randomized, Sham-Controlled, Double-Blind Trial With One-Way Crossover Designed to Assess the Effectiveness and Safety of the Gimer NeuroBlock SCS Trialing System for the Treatment of Chronic Back Pain and/or Lower Limb Pain
Phase: N/A
Role: Lead Sponsor
Start: Mar 1, 2021
Completion: Apr 1, 2022